MF3d
Summary
- Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions.
- The company’s approved drug, Skytrofa, has shown strong sales and has the potential to be a blockbuster.
- Ascendis Pharma’s TransCon PTH, a parathyroid hormone replacement therapy, is awaiting FDA approval and has the potential to capture a significant market share in the treatment of hypoparathyroidism.
Summary
Ascendis Pharma (ASND) may be on track to be cash flow break even by year end 2024. Their core franchise that will enable this includes medicines for rare endocrinology conditions. One was approved in 2021. A second is on track to be approved in the US on May 14th and is currently being launched in Germany and Austria. The third will complete clinical trials in Q4, and the profile has not yet fully emerged. Each may have the potential to be a blockbuster with greater than $1bn in annual sales.
READ FULL ARTICLE HERE!
